Sinopharm Group stock reports lower H1 revenue and profit
Published on 09/30/2026 at 14:50 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Sinopharm Group stock is anchored by weaker first-half results after the company reported RMB 282.8 billion in revenue for the six months ended June 30, 2026, down 1.13 percent year over year. The figures point to pressure in distribution, while retail pharmacy remained the clearest growth engine.
Profit falls as distribution weakens
According to FilingReader on September 22, 2026, Sinopharm's net profit fell 2.95 percent year over year to RMB 5.18 billion for the first half, while net profit attributable to the parent company declined 1.79 percent to RMB 3.40 billion.
Basic earnings per share decreased 1.80 percent to RMB 1.09, and the overall expense ratio improved by 0.27 percentage points to 4.11 percent. The combination gives investors a mixed operating picture: profitability weakened, but cost control provided a partial buffer.
Retail becomes the growth offset
The pharmaceutical distribution segment generated RMB 215.50 billion in revenue, down 1.39 percent, while medical device distribution revenue fell 0.35 percent to RMB 56.85 billion. The retail pharmacy segment moved in the opposite direction, with revenue increasing 8.58 percent to RMB 18.64 billion.
Futunn reported on September 23, 2026, that sales of nationally negotiated and innovative drugs increased 27 percent and 30 percent, respectively, under the company's internal management measures. Sinopharm also disclosed an August agreement to sell a 51 percent stake in Guorui Pharmaceutical, subject to completion.
Hong Kong quote and company profile
Sinopharm Group was last at HKD 14.86 on the Hong Kong Stock Exchange on September 30, 2026 at 4:08 p.m. HKT. Its market capitalization stood at HKD 46.4 billion on the same date, while the quote was HKD 0.12, or 0.81 percent, above the prior close of HKD 14.74.
MarketScreener identifies Sinopharm Group as a pharmaceutical company operating across distribution, medical devices, retail pharmacies and other healthcare businesses. The current results show why retail expansion matters: it is growing while the larger distribution divisions are contracting.
Sinopharm Group stock facts
- Company: Sinopharm Group Co. Ltd.
- Ticker: 1099
- Primary exchange: Hong Kong Stock Exchange
- Price on September 30, 2026: HKD 14.86 at 4:08 p.m. HKT
- Change versus prior close: plus 0.81 percent
- Prior close: HKD 14.74
- Market capitalization: HKD 46.4 billion as of September 30, 2026
- Sector / Industry: Healthcare / Medical distribution
